Infinium Pharmachem Limited is a specialized Indian chemical and pharmaceutical company focused on the niche domain of **Iodine Chemistry**. Headquartered in Gujarat, the company has evolved from a derivative manufacturer into an integrated player spanning the entire value chain—from upstream iodine extraction in the USA to high-value downstream Active Pharmaceutical Ingredients (APIs) and Contrast Media. --- ### **Core Business Model & Product Portfolio** The company operates a modified **Contract Research and Manufacturing Services (CRAMS)** model, providing customized synthesis solutions under its own brand. It serves a diverse global clientele across the pharmaceutical, agrochemical, nutraceutical, and specialty chemical sectors. * **Product Range:** A robust portfolio of **220+ Iodine Derivatives** and **19 APIs**. * **Revenue Mix (as of June 2024):** Approximately **97-98%** of revenue is derived from intermediates, with **1-2%** currently contributed by APIs. * **Key Products:** Iodobenzene diacetate, methyl iodide, and N-iodosuccinimide. * **Strategic Pivot:** The company is aggressively shifting its focus toward high-margin **Contrast Media Intermediates** (e.g., ATIPA) and APIs to enhance EBITDA performance. --- ### **Strategic Forward Integration: The Contrast Media Growth Engine** Infinium is transitioning into the high-value **Contrast Media** segment, which provides raw materials for diagnostic imaging (MRI, PET scans, and X-rays). * **New Infrastructure:** A dedicated manufacturing facility at **GIDC Sojitra, Gujarat**, was commissioned on **January 16, 2026**. * **Key Intermediate:** In-house production of **Atipa dichloride** provides a competitive edge. * **Financial Targets:** * Targeting **₹100 crore** in annual revenue from this segment within **3 years**. * Commercial launch scheduled for **FY 2026** with an initial revenue target of **₹30–₹40 crore**. * **Margin Impact:** This segment carries anticipated **EBITDA margins of ~30%**, which is expected to lift the company’s blended EBITDA margin to approximately **20%**. --- ### **Backward Integration & Global Supply Chain Security** Iodine is a scarce resource, with global supply concentrated in Chile, Japan, and the USA. To insulate itself from price volatility (where iodine accounts for **52-60%** of procurement costs), Infinium has secured its upstream supply. * **U.S. Joint Venture:** Through its subsidiary **Infinium Healthcare Pvt Ltd (51% stake)**, the company holds a **50% stake** in **IBL Elements Inc. (USA)**. * **Proprietary Technology:** The JV utilizes **Air Desorption Technology** to extract **99.9% purity Iodine** from brine (salt water), a byproduct of the oil and gas industry in Oklahoma. * **Supply Agreement:** A **30-year agreement** ensures **100%** of the JV's production (approx. **120-140 MT/year**) is supplied to Infinium at competitive prices. * **Long-term Vision:** The company aims to scale its iodine consumption from the current levels to **800–1,000 MT** by **2030**. --- ### **Global Footprint & Strategic Alliances** Infinium maintains operations in **30+ countries** and is actively expanding its presence in highly regulated markets. | Entity | Location | Holding | Primary Role | | :--- | :--- | :--- | :--- | | **Shanghai Tajilin Industrial Co. Ltd** | China | **51%** | Exclusive distribution and trading in China. | | **Infinium Healthcare Pvt Ltd** | India | **51%*** | API manufacturing and holding company for US JV. | | **Infinium Green Energy Pvt Ltd** | India | **51%** | Bio-coal/Biomass briquettes for captive energy. | | **IBL Elements Inc.** | USA | **50%** | Upstream Iodine extraction and supply. | *\*Management intends to increase holding in Infinium Healthcare to **75%**.* * **Japan Expansion:** A **5-year exclusive distribution agreement** (effective June 2025) with **K Sakai & Company** targets the Japanese semiconductor, electronics, and pharma markets. * **European Union:** Leveraging **REACH Registration** with **7 products registered** and **9 more** in the pipeline/under consideration. Targeting **~₹10 crore** from the EU in **FY 2026**. --- ### **Manufacturing Excellence & Sustainability** * **Location & Capacity:** Primary facility at **GIDC Sojitra, Gujarat**, with an installed capacity of **1,800 MTPA**. * **Compliance:** **WHO-GMP** compliant, **ISO 9001/14001/22000** certified, and **India FDA** approved for API manufacturing. * **Green Energy Initiatives:** * Approved **1.1 MW DC** Solar Power Project (expected March 2026). * Captive bio-coal production via subsidiary (Targeting **10,000 MT**). * **CAPEX:** Total planned investment of **₹21.92 crore**, with **₹15 crore** already deployed. --- ### **Financial Performance & Capital Structure** The company listed on the **NSE SME** platform on **April 17, 2023**, raising **₹25.26 crore**. **Annual Financial Highlights (FY 2023-24):** | Metric | FY 2023-24 (₹) | FY 2022-23 (₹) | Growth (%) | | :--- | :--- | :--- | :--- | | **Total Turnover** | **122.36 Crore** | **101.31 Crore** | **20.78%** | | **Profit Before Tax** | **14.86 Crore** | **12.26 Crore** | **21.16%** | * **Revenue Concentration:** The **Top 10** clients contribute **61.86%** of revenue. The client base grew from **240** to **332** in the last fiscal year. * **Fundraising:** Raised **₹41.10 crore** via preferential allotment in November 2024 at **₹246.57 per share**. * **Debt Profile:** Includes term loans from **SBI** and **Bank of Baroda**, secured by fixed and current assets. * **Management Guidance:** Targeting **₹200+ crore** revenue by **FY26** with sustainable net profit margins of **~10%**. --- ### **Risk Profile & Mitigation** * **Regulatory & Environmental:** The company faced a **temporary closure direction** from the **GPCB** in April 2026 due to third-party waste disposal issues. It also recorded a minor fire incident in February 2026. Management is tightening internal controls and safety protocols. * **Market Competition:** Faces pressure from **multinational corporations** and **duty-free imports** by domestic customers. * **Supply Chain:** High dependence on iodine (up to **60%** of costs) is mitigated by the **US-based JV** and long-term supply contracts. * **Project Cyclicality:** Revenue can fluctuate based on whether client projects are in the **R&D phase** or **commercial phase**, resulting in a **70%** client retention rate. * **Dividend Policy:** The board currently **conserves profits** to fund aggressive **CAPEX** and expansion rather than issuing dividends.